Tlili Hedi sold $1.2M of ATR

Tlili Hedi (Segment President) sold 8,854 shares of APTARGROUP, INC. (ATR) at $135.00 ($1.20M total) on 2026-08-03.

Original reporting
SEC EDGAR · Tlili Hedi
Published Aug 3, 2026, 11:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATR
Neutral
medium confidence
Mentioned
$ATR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRNeutralLow
01

Why it matters

This provides a fresh datapoint on insider selling activity but does not include any new operational, financial, or regulatory development for the company.

02

Market read

Traders may note insider selling as a sentiment input, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

Insider sales can be driven by diversification, planned expenses, or pre-existing personal circumstances; without follow-on buys/sales patterns, signal quality is low.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-03, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for AptarGroup, Inc. (ATR).

Company-level read

Ticker impact

$ATRNeutralMedium confidence
Context

SEC Form 4 shows insider Tlili Hedi, Segment President at AptarGroup, sold 8,854 shares at $135 on 2026-08-03.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal without broader context.

Evidence & confidence

Form 4 insider sales are common and the article provides no accompanying guidance, deal, or operational change. The transaction is sizable in dollars but lacks evidence of new company-specific fundamentals.

Market effects

No sector-level implications; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity or tax-related, especially with no 10b5-1 plan cited, so it may not reflect bearish fundamentals.

Key entities

  • AptarGroup, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Tlili Hedi

    Segment President who sold shares via an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.